retatrutide trial status Reta clinical data & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, GIP 🚨 Retatrutide TRIUMPH-1 Phase 3

The Biological Rebound Stopping weight loss drugs often triggers a biological rebound: hormonal and metabolic shifts push the body back toward its prior weight

GBB works by converting to L-carnitine through an enzymatic reaction catalyzed by -butyrobetaine hydroxylase

Higher doses have higher efficacy, but they also increase the risk of gastrointestinal side effects

According to a 2025 report from the BBC, patients often describe it as both emotionally isolating and physically uncomfortable

Gastrointestinal side effects represent one of the most common challenges when starting GLP-1 receptor agonist therapy, with diarrhea occurring in approximately one-quarter of patients during initial dose escalation

However, the risk increases if you are also taking insulin or a sulfonylurea (such as gliclazide)